Does Benzene Cause Acute Myeloid Leukemia?

From General Health to Occupational Hazard Awareness

General health and science information often addresses broad wellness topics and disease prevention without focusing on specific environmental or occupational hazards. This foundation provides a useful starting point for understanding how everyday exposures may influence long-term health outcomes. Transitioning from this general perspective, attention naturally shifts toward more targeted concerns, such as the role of chemical agents in occupational settings. In particular, benzene—a common industrial solvent and component of crude oil—has been extensively studied in relation to workplace exposure. Workers in industries such as petrochemical refining, rubber manufacturing, and chemical processing may encounter benzene through inhalation or dermal contact. The shift from general health awareness to occupational exposure concern involves recognizing that certain environments carry elevated risks that require specific monitoring and regulation. This bridge concept allows for a focused examination of how benzene exposure, especially in occupational contexts, relates to the development of acute myeloid leukemia, without delving into disease-specific mechanisms. The transition maintains a neutral academic tone, moving from broad health principles to a more precise inquiry into workplace hazards and their potential health implications.

Benzene as a Myelotoxin and Human Carcinogen

Benzene is a well-established myelotoxin and recognized human carcinogen. Chronic exposure to benzene is associated with an increased risk of developing acute myeloid leukemia (AML), a hematologic malignancy characterized by the rapid proliferation of abnormal myeloid progenitor cells in the bone marrow and peripheral blood. The clinical presentation of AML typically includes symptoms related to bone marrow failure, such as fatigue, pallor, infection, and bleeding, along with signs of extramedullary involvement. Diagnosis is confirmed by bone marrow aspiration and biopsy demonstrating at least 20% blasts of myeloid lineage, along with cytogenetic and molecular profiling to guide prognosis and treatment. Benzene is metabolized in the liver and bone marrow to reactive intermediates, including benzene oxide, phenol, hydroquinone, and benzoquinone. These metabolites can cause direct DNA damage, generate oxidative stress, and induce inflammation. The carcinogenic ability of benzene has been reported, and chronic exposure to benzene can be one of the risk elements for solid cancers and hematological neoplasms (https://pubmed.ncbi.nlm.nih.gov/34069279/). Benzene is acknowledged as a myelotoxin, and it is able to augment the risk for the onset of acute myeloid leukemia, myelodysplastic syndromes, aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279/). Possible mechanisms of benzene initiation of hematological tumors have been identified, as a genotoxic effect, an action on oxidative stress and inflammation and the provocation of immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). However, it is becoming evident that genetic alterations and the other causes are insufficient to fully justify several phenomena that influence the onset of hematologic malignancies (https://pubmed.ncbi.nlm.nih.gov/34069279/).

Mode of Action and Epidemiological Evidence

The mode of action (MOA) for AML development leading to mortality is anticipated to include multiple earlier key events, which can be observed in hematotoxicity and genetic toxicity in peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013/). Occupational exposure to benzene at levels of 10 ppm or more has been associated with increased risk of acute myeloid leukaemia (AML) (https://pubmed.ncbi.nlm.nih.gov/33429013/). Prevention of these early events would lead to prevention of the apical, adverse outcomes, the morbidity and mortality caused by the myelodysplastic syndromes (MDS) and AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). Incorporation of key event information should modify the risk model, but few modification approaches have been suggested (https://pubmed.ncbi.nlm.nih.gov/33429013/). Epidemiological evidence further supports the causal relationship between benzene exposure and AML. Previous studies established a causal relationship between occupational benzene exposure and acute myeloid leukemia (AML) (https://pubmed.ncbi.nlm.nih.gov/38727681/). In a national cohort from Switzerland, we found that occupational exposure to benzene is associated with elevated mortality risks for AML, diffuse large B-cell lymphoma, and possibly follicular lymphoma (https://pubmed.ncbi.nlm.nih.gov/38727681/). Additionally, a meta-analysis of childhood cancer studies reported increased risks of acute myeloid leukemia (AML, OR: 1.22, 95% CI: 1.02-1.46; 4 studies; I2 = 0.0%) associated with benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/). These findings indicate that benzene exposure elevates AML risk across different age groups and exposure settings.

Risk Communication and Preventive Measures

From a risk communication perspective, the adequacy of warnings regarding benzene and AML is critical. Given the established causal link, product labels and safety data sheets for benzene-containing materials should clearly state the risk of AML and other hematologic malignancies. Workers in industries with potential benzene exposure—such as chemical manufacturing, petroleum refining, and rubber production—must receive appropriate training and protective equipment. For affected patients, causation-related considerations include documenting the duration and intensity of exposure, latency period, and absence of other strong risk factors. The timeline between benzene exposure and documented harm can vary, but occupational studies indicate that elevated AML risk is observed after chronic exposure, often over years to decades. Early detection of hematotoxicity through regular blood monitoring in exposed populations may help identify individuals at risk before AML develops. In summary, the evidence consistently demonstrates that benzene causes acute myeloid leukemia through multiple mechanistic pathways, including genotoxicity, oxidative stress, and immunosuppression. Epidemiological studies confirm elevated AML risks in both occupational and environmental settings. Adequate warnings and preventive measures are essential to reduce exposure and subsequent disease burden.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the evidence that benzene causes acute myeloid leukemia?

Benzene is a well-established myelotoxin and human carcinogen. Multiple studies have demonstrated a causal relationship between occupational benzene exposure and acute myeloid leukemia (AML). Mechanistically, benzene metabolites cause DNA damage, oxidative stress, and immunosuppression. Epidemiological studies show increased AML risk in workers exposed to benzene at levels of 10 ppm or more, and meta-analyses confirm elevated risks in both occupational and environmental settings (https://pubmed.ncbi.nlm.nih.gov/34069279/, https://pubmed.ncbi.nlm.nih.gov/33429013/, https://pubmed.ncbi.nlm.nih.gov/38727681/, https://pubmed.ncbi.nlm.nih.gov/41485753/).

What are the symptoms and diagnosis of acute myeloid leukemia?

Acute myeloid leukemia (AML) typically presents with symptoms related to bone marrow failure, including fatigue, pallor, infection, and bleeding, along with signs of extramedullary involvement. Diagnosis is confirmed by bone marrow aspiration and biopsy demonstrating at least 20% blasts of myeloid lineage, along with cytogenetic and molecular profiling to guide prognosis and treatment.

How can benzene exposure be prevented in the workplace?

Preventive measures include using engineering controls such as ventilation and closed systems, providing personal protective equipment (e.g., respirators, gloves), implementing regular air monitoring, and conducting health surveillance including blood counts. Product labels and safety data sheets should clearly state the risk of AML and other hematologic malignancies. Workers must receive appropriate training on safe handling and emergency procedures.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Benzene exposure and a confirmed Acute Myeloid Leukemia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.